Table 1 Clinicopathological features of 842 breast cancer patients followed by thyroid cancer and 332,424 breast cancer only patients
Breast cancer then develop thyroid cacer, n = 842 | Breast cancer only, n = 332,424 | p-value | |||
|---|---|---|---|---|---|
n | % | n | % | ||
Age at diagnosis | < 0.001 | ||||
Median age (years) | 54 [47, 63] | 59 [49, 71] | |||
≤ 40 | 95 | 11.28% | 25,787 | 7.76% | |
41–50 | 220 | 26.13% | 69,214 | 20.82% | |
51–60 | 257 | 30.52% | 80,754 | 24.29% | |
61–70 | 172 | 20.43% | 70,475 | 21.20% | |
> 70 | 98 | 11.64% | 86,194 | 25.93% | |
Race | 0.106 | ||||
White | 660 | 78.39% | 267,366 | 80.43% | |
Black | 77 | 9.14% | 30,469 | 9.17% | |
American Indian | 6 | 0.71% | 2267 | 0.68% | |
Asian or Pacific Islander | 97 | 11.52% | 30,311 | 9.12% | |
Unknown | 2 | 0.24% | 2011 | 0.60% | |
Tumor site | 0.912 | ||||
Central portion | 55 | 6.53% | 18,578 | 5.59% | |
Nipple | 3 | 0.37% | 1889 | 0.66% | |
Upper-inner | 90 | 10.69% | 34,580 | 10.40% | |
Lower-inner | 44 | 5.22% | 17,684 | 5.32% | |
Upper-outer | 301 | 35.75% | 116,708 | 35.11% | |
Lower-outer | 56 | 6.65% | 22,500 | 6.77% | |
Overlapping lesion | 167 | 19.83% | 68,460 | 20.59% | |
Unknown | 126 | 14.96% | 52,033 | 15.65% | |
Tumor size | < 0.001 | ||||
T ≤ 20 mm | 509 | 60.45% | 186,656 | 56.15% | |
21 mm < T ≤ 50 mm | 235 | 27.91% | 88,752 | 26.70% | |
T > 50 mm | 39 | 4.63% | 14,467 | 4.35% | |
Unknown | 59 | 7.01% | 42,553 | 12.80% | |
Positive lymph nodes | 0.358 | ||||
0 | 526 | 62.47% | 198,449 | 59.70% | |
1–3 | 174 | 20.66% | 71,560 | 21.53% | |
4–9 | 55 | 6.53% | 22,700 | 6.83% | |
≥ 10 | 27 | 3.21% | 14,593 | 4.38% | |
Unknown | 60 | 7.13% | 25,127 | 7.56% | |
Histology | 0.650 | ||||
Infiltrating duct carcinoma | 689 | 81.83% | 267,864 | 80.57% | |
Lobular carcinoma | 71 | 8.43% | 29,570 | 8.90% | |
Mixed | 82 | 9.74% | 34,993 | 10.53% | |
Grade | 0.351 | ||||
1 | 136 | 16.15% | 56,672 | 17.05% | |
2 | 350 | 41.57% | 130,229 | 39.18% | |
3 | 283 | 33.61% | 111,645 | 33.58% | |
4 | 13 | 1.54% | 4636 | 1.39% | |
Unknown | 60 | 7.13% | 29,247 | 8.80% | |
ER | 0.908 | ||||
Positive | 601 | 71.38% | 234,140 | 70.43% | |
Negative | 155 | 18.41% | 62,340 | 18.76% | |
Borderline | 2 | 0.24% | 1062 | 0.32% | |
Unknown | 84 | 6.41% | 34,882 | 10.49% | |
PR | 0.090 | ||||
Positive | 532 | 63.18% | 197,737 | 59.48% | |
Negative | 202 | 24.00% | 92,509 | 27.83% | |
Borderline | 6 | 0.71% | 2069 | 0.62% | |
Unknown | 102 | 12.11% | 40,113 | 12.07% | |
HER-2 | 0.061 | ||||
Positive | 13 | 1.55% | 5966 | 1.80% | |
Negative | 45 | 5.34% | 32,120 | 9.66% | |
Unknown | 784 | 93.11% | 294,341 | 88.54% | |